Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.
1. A genetically engineered yeast comprising a polynucleotide encoding an immunostimulatory, full-length high mobility group box (HMGB1) polypeptide and a GP1-anchored alpha-agglutinin polypeptide from Saccharomyces cerevisiae , wherein the HMGB1 polypeptide is connected to the C-terminus of the alpha-agglutinin polypeptide, and wherein the genetically engineered yeast displays the HMGB1 polypeptide on the surface of the yeast.
2. The genetically engineered yeast of claim 1 , further comprising a polynucleotide encoding an antigenic polypeptide, wherein the antigenic polypeptide is displayed on the surface of the yeast.
3. The genetically engineered yeast of claim 2 , wherein the antigenic polypeptide and the HMGB1 polypeptide are a part of a fusion protein.
4. The genetically engineered yeast of claim 2 , wherein the antigenic polypeptide is selected from the group consisting of an Influenza polypeptide, a Campylobacter polypeptide, a Clostridium polypeptide, a Salmonella polypeptide, an Eimeria polypeptide, and a tumor associated polypeptide.
5. The genetically engineered yeast of claim 2 , wherein the antigenic polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 39 to 56 and SEQ ID NOs: 58 to 93.
6. The genetically engineered yeast of claim 1 , wherein the yeast is Pichia.
7. The genetically engineered yeast of claim 1 , wherein the HMGB1 polypeptide comprises an amino acid sequence with at least 98% identity to a sequence selected from the group consisting of SEQ ID NOs: 2-30 and SEQ ID NOs: 94-105.
8. A pharmaceutical composition comprising the genetically engineered yeast of claim 2 and a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 8 , wherein the pharmaceutically acceptable carrier is acceptable for oral or nasal administration.
10. The pharmaceutical composition of claim 8 , wherein the yeast is not capable of replication or is inactivated or killed.
11. A method of enhancing an immune response in a vertebrate or mammalian subject by administering the pharmaceutical composition of claim 8 to the subject in an amount effective to enhance the immune response to the antigenic polypeptide in the subject.
12. The method of claim 11 , wherein the yeast is not capable of replication or is inactivated or killed.
13. The method of claim 11 , wherein the subject is a human, cow, cat, dog, pig, fish, bird or poultry.